Interventional Cardiology Devices Market By Top Key Players - Medtronic, Boston Scientific, Abbott, Medinol

1
Global Interventional Cardiology Devices Market
By Top Key Players Medtronic, Boston
Scientific, Abbott
2

• Interventional cardiology is a branch of
  cardiology that utilizes nonsurgical,
  catheter-based treatments for structural heart
  diseases. It makes use of devices such as
  catheters sheaths, guidewires, balloons,
  stents, vascular closure devices, atherectomy
  devices, intravascular ultrasound (IVUS), and
  other devices to repair narrowed arteries,
  damaged or weakened blood vessels, heart valve
  disorders, and congenital heart diseases.
• The Global Interventional Cardiology
  Devices Market valued at US 6.7 billion in 2021
  is set to witness a growth rate of 2 to 3 in
  the next 5 years. The rising geriatric population
  corresponding rise in the prevalence of
  coronary artery diseases, rising occurrence of
  diabetes concomitant increased risk of coronary
  heart disease, technical developments in
  interventional cardiology devices, and favourable
  reimbursements for interventional cardiology
  procedures are some of the key factors driving
  the global interventional cardiology devices
  market.
• APAC to Witness Highest Growth in the Next Five
  Years
• An increasing occurrence of cardiovascular
  diseases hypertension, a higher degree of unmet
  clinical needs, and rising affluence are creating
  ample opportunities for the interventional
  cardiology devices market in the APAC region. The
  development of the interventional cardiology
  devices market in the APAC is likely to be driven
  by China and India. Considering the lucrative
  prospects of the interventional cardiology
  devices market in the APAC region, prominent
  companies have expanded their footprint in the
  region.
• For instance,
• In March 2022, Boston Scientific expanded its
  footprint in India with its second RD Center.
  The new RD Center addresses the needs of the
  patients in India, APAC, and around the world. It
  also provides expertise to all of the companys
  diverse therapy areas, namely interventional
  cardiology, peripheral interventions, cardiac
  rhythm management, endoscopy, neuromodulation,
  urology, and pelvic health

3

• Abbott also intends to expand coverage and
  resources in training programs related to
  cardiovascular treatment in China. Abbott owns
  two training centers in China. The Abbott Medical
  Advanced Technology Center in Beijing provides
  doctors with first-class cardiological learning
  experiences and practice opportunities. The
  Crossroads-Abbott Academic Center in Shanghai
  provides interventional treatment training for
  physicians from different regions in China,
  making medical treatment and standardized
  treatment and care more accessible to patients in
  remote areas
• China is one of the most prominent markets for
  cardiovascular diseases. The demand from patients
  to be treated as well as doctors to get trained
  is humongous. This is why interventional
  cardiology device manufacturers are investing in
  China."- Director, Leading Stent Manufacturer,
  United States
• Explore Premium Report on Interventional
  Cardiology Devices Market _at_ https//meditechinsigh
  ts.com/interventional-cardiology-devices-market/
• Technological Advancements Drive the Market 
• The interventional cardiology devices market is a
  technology-driven market and is noticeable by
  product enhancements/innovations.
• For instance,
• In May, 2022, Medtronic received U.S. FDA
  approval for the Onyx Frontier drug-eluting
  stent (DES). The Onyx Frontier DES is used for
  the treatment of patients with coronary artery
  disease (CAD). It offers an innovative delivery
  system and builds upon the acute performance and
  clinical data from the Resolute Onyx
  drug-eluting stent

4

• In April 2022, Translumina launched VIVO ISAR,
  its latest generation dual drug polymer-free
  coated stent (DDCS), in various international
  markets including Europe
• Organic and Inorganic Growth Strategies Adopted
  by Players to Establish Their Foothold
• The interventional cardiology devices market is
  characterised by the presence of both established
  and new players. Players operating in the market
  adopt both organic and inorganic growth
  strategies such as acquisitions, and new product
  launches to gain market share.
• For instance,
• In April 2022, Transit Scientific announced the
  FDA clearance of its XO Cross Support Catheter
  Platform to include coronary use. The platform is
  indicated to guide and support a guidewire during
  access of the peripheral or coronary vasculature,
  allow for wire exchanges, and provide a conduit
  for delivery of saline solutions or diagnostic
  contrast agents
• In April 2022, Boston Scientific announced the
  close of its acquisition of Baylis Medical
  Company Inc., a company that offers advanced
  transseptal access solutions as well as
  guidewires, sheaths and dilators used to support
  catheter-based left-heart procedures. The
  acquisition allows Boston Scientific to integrate
  the Baylis platforms with its existing
  electrophysiology and structural heart offerings,
  further strengthening its position in the
  cardiology market

5

• The interventional cardiology devices market is
  anticipated to continue to grow in the coming
  years due to rising cardiovascular cases, growth
  opportunities in the APAC region, technical
  developments in interventional cardiology
  devices, and favorable reimbursement in key
  markets.
• Competitive Landscape Analysis of Interventional
  Cardiology Devices Market
• The interventional cardiology devices market is
  marked by the presence of players such
  as Medtronic, Boston Scientific, Abbott, Medinol,
  Biotronik, SMT, Terumo, Lepu Medical, Microport,
  among others.
• For More Comprehensive Insights, Contact Us
  _at_ https//meditechinsights.com/contact-us/
• About Medi-Tech Insights
• Medi-Tech Insights is a healthcare-focused
  business research insights firm. Our clients
  include Fortune 500 companies, blue-chip
  investors hyper-growth start-ups. We have
  completed 100 projects in Digital Health,
  Healthcare IT, Medical Technology, Medical
  Devices Pharma Services.
• Contact
• Ruta Halde
• Associate, Medi-Tech Insights
• 32 498 86 80 79
• info_at_meditechinsights.com